Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 5, 1999, Pages 233-240

  Blanco Serrano, B ^a   Otero, M J ^a   Santos Buelga, D ^b   Garcia Sanchez M J ^b   Serrano, J ^a   Dominguez Gil A ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Drug interactions; NONMEM; Population pharmacokinetics; Therapeutic drug monitoring; Valproic acid

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CALCULATION; COMPARTMENT MODEL; COMPUTER PROGRAM; DATA ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; EPILEPSY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BODY WEIGHT; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RETROSPECTIVE STUDIES; VALPROIC ACID;

EID: 0033399925     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5     Document Type: Article

References (36)

1. Mattson RH. Antiepileptic drug monitoring: a reappraisal. Epilepsia 1995; 36: S22-S29.
2. Eadie MJ. Indications for plasma drug monitoring in patients with epilepsy. Implications for reducing costs. Pharmacoeconomics 1997; 11: 343-349.
3. Grasela TH, Sheiner LB. Pharmacostatistical modeling for observational data. J Pharmacokinet Biopharm 1991; 19: 25S-36S.
4. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameter from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-479.
5. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-372.
6. Beal SL, Sheiner LB. NONMEM User's Guide. NONMEM Project Group, University of California, San Francisco, 1992.
7. Mihaly GW, Vajda FJ, Miles JL, Louis WJ. Single and chronic dose pharmacokinetics of sodium valproate in epileptic patients. Eur J Clin Pharmacol 1979; 16: 23-29.
8. Perucca E, Gatti G, Frigo GM, Crema A. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 313-318.
9. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21: 736-743.
10. Nitsche V, Mascher H. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia 1982; 23: 153-162.
11. Perucca E, Gatti G, Frigo GM, Crema A, Calzetti S, Visintini D. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 495-499.
12. Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to Midazolam. J Pharmacokinet Biopharm 1991; 19: 377-384.
13. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22: 447-467.
14. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.
15. Vajda FJE, Drummer OH, Morris PM, McNeil JJ, Bladin PF. Gas chromatographic measurement of plasma levels of sodium valproate: tentative therapeutic range of a new anticonvulsivant in the treatment of refractory epileptics. Clin Exp Pharmacol Physiol 1978; 5: 67-73.
16. Gram L, Flachs H, Wurtz-Jorgensen A, Parnas J, Anderson B. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 1979; 20: 303-312.
17. Bowdle TA, Indravandan HP, Levy RH, Wilensky AJ. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980; 28: 486-492.
18. Yukawa E. A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. J Pharm Pharmacol 1995; 47: 1048-1052.
19. Levy RH, Schen DD. Valproate: absorption, distribution and excretion. In: Levy RH, Mattson RH, Meldrum BS, Penry JK, Dreifuss FE (eds) Antiepileptic Drugs. New York: Raven Press, 1989; 583-599.
20. Delgado Iribarnegaray F, Santos Buelga D, Garcia Sanchez MJ, Otero MJ, Falcão AC, Domínguez-Gil A. Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther Drug Monit 1997; 19: 132-139.
21. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet 1996; 31: 470-493.
22. Schapel GJ, Beran RG, Doecke CJ, O'Reilly WJ, Reece PA, Rischbieth RHC, Sansom LN, Stanley PE. Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study. Eur J Clin Pharmacol 1980; 17: 71-77.
23. Cloyd JC, Kryel RL, Fischer JH. Valproic acid pharmacokinetics in children. II. Discontinuation of concomitant antiepileptic drug therapy. Neurology 1985; 35: 1623-1627.
24. Chiba K, Suganuma T, Ishizaky T, Iriki T, Hori M. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug therapy. J Pediatr 1985; 106: 653-658.
25. Sackellares JC, Sato S, Dreifuss FE, Penry JK. Reduction of steady-state valproate levels by other antiepileptic drugs. Epilepsia 1981; 22: 437-441.
26. De Wolff FA, Peters ACB, van Kempen GMJ. Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate. Neuropediatrics 1982; 13: 10-13.
27. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982; 65: 504-523.
28. Cloyd JC, Fischer JH, Kryel RL, Kraus DM. Valproic acid phaimacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 1993; 53: 22-29.
29. Hoffman F, von Unruh GE, Jancik BC. Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy. Eur J Clin Pharmacol 1981; 19: 383-385.
30. May T, Rambeck B. Serum concentration of valproic acid: influence of dose and comedication. Ther Drug Monit 1985; 7: 387-390.
31. Pockrajac M, Miljkovi B, Varagi VM, Levi Z. Pharmacokinetic interaction between valproic acid and phenobarbital. Biopharm Drug Dispos 1993; 14: 81-86.
32. Reunanen MI, Luoma P, Myllyla P, Hokkanen E. Low serum valproic acid concentrations in epileptic patients on combination therapy. Curr Ther Res 1980; 28: 455-462.
33. Scheyer RD, Mattson RH. Valproic acid: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic Drugs. New York: Raven Press, 1995; 621-631.
34. Levy RH, Schen DD. Valproic acid: absorption, distribution and excretion. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic Drugs. New York: Raven Press, 1995; 605-619.
35. Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole and multidrug therapy. Ther Drug Monit 1986; 8: 411-416.
36. Kondo T, Otani K, Hirano T, Kaneko S, Fukushima Y. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid. Br J Clin Pharmacol 1990; 29: 116-119.